TREATING INFLAMMATION WITH SOLUBLE HYBRID FCGAMMA RECEPTORS

• US 20200131245A1
• Filed: 01/08/2020
• Published: 04/30/2020
• Est. Priority Date: 06/27/2008
• Status: Active Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: BIRKS, Carl W., FOX, Brian A.., RIXON, Mark W., ELLSWORTH, Jeff L.
• Application Number:
  US16/737,039
• Publication Number:
  US 20200131245A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 14/70535 Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Abstract

Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.

Claims

1. A method of reducing IgG-mediated inflammation in a subject, the method comprising:

administering to the subject with IgG-mediated inflammation a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;

42, amino acid residues 21-286 of SEQ ID NO;

44;

or amino acid residues 21-286 of SEQ ID NO;

46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.

2. The method of claim 1, wherein the IgG-mediated inflammation is immune complex-mediated.

3. A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising:

administering to the subject a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;

42, amino acid residues 21-286 of SEQ ID NO;

44, or amino acid residues 21-286 of SEQ ID NO;

46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.

4. The method of claim 3, wherein the IgG-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA);

systemic lupus erythematosus (SLE);

idiopathic thrombocytopenia purpura (ITP);

Sjogren'"'"'s syndrome;

Guillain-Barre syndrome; and

Goodpasture'"'"'s syndrome.

5. A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising:

administering to the subject a therapeutically effective amount of a composition comprising a soluble polypeptide and a pharmaceutically acceptable carrier, wherein the soluble polypeptide comprises amino acid residues 43-310 of SEQ ID NO;

42, amino acid residues 21-286 of SEQ ID NO;

44, or amino acid residues 21-286 of SEQ ID NO;

46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.

6. The method of claim 5, wherein the IgG-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA);

systemic lupus erythematosus (SLE);

idiopathic thrombocytopenia purpura (ITP);

Sjogren'"'"'s syndrome;

Guillain-Barre syndrome; and

Goodpasture'"'"'s syndrome.